To Evaluate the Efficacy and Safety of RSS0393 Ointment in Patients With Plaque Psoriasis Phase II Study

This is a standard placebo-controlled Phase 2 psoriasis design, which is a plus: plaque psoriasis is an established dermatology setting, topical treatment is appropriate, and the primary endpoint—PGA 0/1 with at least a 2-point improvement at 8 weeks—is clinically meaningful and commonly used. If the drug has real activity, placebo separation is achievable on this endpoint. Offsetting that, the trial record provides almost no supportive asset-specific evidence: no prior efficacy signal, no dose-ranging context, and only a very sparse summary, so the base technical success rate should stay modest. The biggest negative is operational. The study is still listed as Not Yet Recruiting even though the stated primary completion date is already in the past, which raises real risk of start-up failure, delay, registry inaccuracy, or delayed or absent disclosure. Sponsor scale helps somewhat, but execution and visibility risks are substantial. Netting design quality against weak supporting context and major operational red flags leaves YES below 50%.

This is a Phase 2 placebo-controlled trial of RSS0393 ointment for plaque psoriasis by Jiangsu HengRui. The primary endpoint is PGA 0/1 with ≥2-point improvement at 8 weeks, a standard and well-accepted regulatory endpoint. Several factors weigh against a high YES probability: (1) The trial status is 'Not Yet Recruiting' despite having passed its estimated primary completion date of March 2026 by over a month. This is a major red flag—it suggests significant operational delays, possible regulatory or manufacturing issues, or protocol amendments. A trial that hasn't even begun recruiting is very unlikely to have positive results to report anytime soon, and the question asks about positive results resolution. (2) Phase 2 base rates for dermatology topicals are moderate (~40-55%), but this is a novel compound from a Chinese sponsor with no disclosed Phase 1 efficacy signal. (3) Topical psoriasis is a competitive space with established treatments, raising the efficacy bar. (4) The disconnect between the timeline and recruitment status introduces substantial uncertainty about whether the trial will even complete as designed. Weighting the operational risk heavily, I estimate ~40% intrinsic YES probability.

This is a Phase 2 plaque psoriasis trial for RSS0393 ointment with a standard PGA endpoint (proportion achieving clear/near-clear with ≥2-point improvement at 8 weeks). Phase 2 carries inherently high failure risk, typically 60-70% fail to advance. Key concerns: (1) status shows 'Not Yet Recruiting' despite primary completion date having passed 32 days ago - significant execution risk or possible data delay; (2) no prior efficacy data provided for RSS0393, leaving no basis to assess therapeutic potential; (3) sponsor Jiangsu HengRui (600276.SH) has general pharma capabilities but no disclosed track record with this asset. Without Phase 1 safety/efficacy signals or mechanistic differentiation, intrinsic probability favors failure. Standard PGA endpoint is validated but doesn't improve baseline success odds for an uncharacterized molecule. Estimate ~35% intrinsic YES probability, below market pricing.

This Phase 2 trial for a topical psoriasis ointment from a credible sponsor has a reasonable endpoint (PGA response). However, the trial status is 'Not Yet Recruiting' as of the analysis date, which is over a month after the estimated primary completion date. This significant delay suggests serious operational issues, likely in patient enrollment or site activation. The lack of any recruitment progress introduces high execution and disclosure risk. While the drug mechanism may be sound, the stalled status materially lowers the probability of generating timely, positive results. The intrinsic odds are thus slightly below even.

This Phase 2 trial tests RSS0393 ointment versus placebo in plaque psoriasis patients, using a standard primary endpoint: PGA score of 0/1 with ≥2-point improvement at 8 weeks. The endpoint is high-quality, reliable, and widely accepted for topical psoriasis therapies in mild-to-moderate disease. Patient population is typical ('Psoriatic Subjects'), likely adults with moderate plaque psoriasis suitable for topical treatment. Sponsor Jiangsu HengRui Medicine (600276.SH) is a major Chinese pharma with proven execution in dermatology and global trials. However, no prior data is available—no Phase 1 results, dose-finding, or efficacy signals for RSS0393, leaving its mechanism and potency unknown. Critically, the trial status is 'Not Yet Recruiting' as of April 2026, 32 days past the estimated primary completion (March 1, 2026), signaling severe operational delays, potential recruitment issues in psoriasis (competitive space), or regulatory setbacks. This elevates execution risk substantially. Disclosure risk is moderate; Chinese sponsors often report transparently but may emphasize positives. Phase 2 topical psoriasis success rates average ~40-50%, but delays and no priors pull odds down to 38% for statistically significant PGA superiority.

This Phase 2 psoriasis trial for RSS0393 ointment faces significant headwinds. The trial status is 'Not Yet Recruiting' despite an estimated primary completion date of March 1, 2026, which was 32 days ago. This operational discrepancy suggests severe delays or administrative issues, undermining confidence in study execution. As a Phase 2 dose-finding study, success is not guaranteed even if the drug is active. The primary endpoint (PGA 0-1 with 2+ point improvement) at 8 weeks is a standard but competitive efficacy bar. Without disclosed Phase 1 data or a known mechanism of action, intrinsic efficacy is speculative. Given the missed completion timeline and lack of recruiting activity, the probability of a timely positive result is substantially reduced, warranting a NO call.

Phase 2 psoriasis trials face substantial efficacy hurdles. RSS0393 is a novel ointment with no disclosed mechanism or prior clinical data, creating high translational uncertainty. The PGA endpoint at 8 weeks is standard but stringent—historical placebo rates are 5-10% and active comparators often hit 40-60%. The trial remains 'Not Yet Recruiting' despite a March 2026 primary completion target that has already passed (-32 days), signaling operational delays and potential execution risk. Chinese sponsor with no prior psoriasis regulatory track record adds disclosure and quality concerns. Without proof-of-concept data or biomarker rationale, the intrinsic probability sits below 40%.

RSS0393 is a highly potent, selective PDE-4 inhibitor being developed by Hengrui Medicine for the topical treatment of plaque psoriasis. The PDE-4 pathway is a thoroughly validated and de-risked target for this indication, with approved analogs like roflumilast confirming the clinical viability of the mechanism. Early clinical data from the Phase 1 trial established a clear proof-of-concept, demonstrating a robust -56.8% mean PASI reduction compared to just -25.3% for the vehicle, alongside superior PGA responses and a clean local safety profile. Although the current registry status shows 'Not Yet Recruiting' with a technically lapsed primary completion date of March 2026, this discrepancy is primarily an artifact of administrative lag. Hengrui officially received NMPA clearance to commence clinical trials for the RSS0393 ointment in September 2025. This late clearance naturally pushed the operational timeline back by at least six months, making the original March 2026 estimate obsolete. Stale ClinicalTrials.gov updates are historically very common for Chinese trial sponsors. Therefore, the trial delay does not indicate any fundamental drug failure or high cancellation risk. The intrinsic probability of achieving a positive Phase 2 result remains fundamentally strong due to the validated mechanism and compelling preliminary efficacy.

The trial is in Phase 2, which has a relatively high failure rate. The primary endpoint is a common measure for plaque psoriasis but achieving a ≥2 points improvement from baseline to a PGA score of 0 or 1 within 8 weeks might be challenging. The sample size and study design details are not provided, adding uncertainty. The sponsor, Jiangsu HengRui Medicine Co., Ltd., has a mixed track record with previous trials. Overall, while there are positive aspects, the risk seems significant.